Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28958334.
- Also identified by DOI 10.1016/j.jacc.2017.08.037.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures.
Medical subject headings
- Coronary Artery Disease
- Platelet Aggregation Inhibitors